ASP Isotopes (NASDAQ:ASPI) PT Raised to $5.50

ASP Isotopes (NASDAQ:ASPI) had its target price hoisted by analysts at HC Wainwright from $5.25 to $5.50 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 77.42% from the company’s previous close.

ASP Isotopes Stock Down 1.9 %

Shares of ASPI stock traded down $0.06 on Wednesday, reaching $3.10. 557,004 shares of the stock were exchanged, compared to its average volume of 588,420. ASP Isotopes has a twelve month low of $0.28 and a twelve month high of $4.97. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $151.65 million, a price-to-earnings ratio of -6.33 and a beta of 5.03. The business’s 50 day moving average price is $3.66 and its 200 day moving average price is $2.36.

Insider Transactions at ASP Isotopes

In other ASP Isotopes news, Director Robert John Andrew Ryan purchased 15,596 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average cost of $2.35 per share, with a total value of $36,650.60. Following the completion of the acquisition, the director now directly owns 537,055 shares of the company’s stock, valued at approximately $1,262,079.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 26.30% of the company’s stock.

Institutional Investors Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of ASP Isotopes by 761.7% during the fourth quarter. Vanguard Group Inc. now owns 176,314 shares of the company’s stock worth $316,000 after purchasing an additional 155,853 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of ASP Isotopes in the 4th quarter valued at about $26,000. GSA Capital Partners LLP purchased a new position in ASP Isotopes during the 4th quarter worth approximately $608,000. Citadel Advisors LLC purchased a new position in ASP Isotopes during the 4th quarter worth approximately $187,000. Finally, Rathbones Group PLC acquired a new position in ASP Isotopes during the fourth quarter worth approximately $272,000. 16.80% of the stock is owned by hedge funds and other institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry.